Neuriva vs Prevagen: What the Evidence Says in 2026

If you want one clear winner in the Neuriva vs Prevagen debate, the research does not name one. No published human trial tested the products against each other. Each is sold as a brain health supplement for memory and cognitive function, but the clinical evidence does not establish a winner.

Neuriva has one short finished-formula trial with selected positive and several null results. Prevagen also has a published trial, but its major memory claims later faced a federal judgment.

There is another catch. The Neuriva study tested 100 mg of whole coffee cherry extract and 100 mg of phosphatidylserine (PS). The paper calls the test product Neuriva, not Neuriva Original. In this comparison, “Original trial mix” means that 100 mg/100 mg formula. Current Neuriva Plus has twice as much coffee fruit extract, the same amount of PS, and added B vitamins. It is a different product. The trial cannot simply be used as proof that Plus works.

The 100 mg/100 mg Neuriva formula has the more useful finished-product trial record, but the edge is narrow. An Original bottle must match that formula. The study was short, paid for by Reckitt, and did not show a clear gain in self-rated daily memory. Prevagen has weaker support for its broad memory pitch. A 2024 federal judgment says the jury found that none of eight challenged claims was supported by competent and reliable scientific evidence.

Neuriva vs Prevagen at a glance

Short verdict: The 100 mg/100 mg Neuriva trial formula has a slight evidence edge when an Original bottle matches it. That does not make Neuriva clinically proven.

Prevagen's published abstract looks positive, but the later legal record makes its broad ad claims hard to defend. Neither product should replace medical care for memory loss.

Which Neuriva formula did the clinical research test?

Neuriva is a brand family, not one product. It sells Original, Plus, gummies, and other versions. Prevagen also comes in several strengths and forms.

A fair comparison must name the exact bottle.

The study paper calls the product Neuriva and gives 100 mg of whole coffee cherry extract and 100 mg of PS per daily serving. It does not call the product Original. “Original trial mix” is used here to keep that formula distinct from Plus. The study did not test the added B vitamins found in Plus.

Neuriva Plus is a common shelf choice. Its current Schiff Vitamins label names two primary active ingredients: 200 mg of coffee fruit extract and 100 mg of PS. It also lists vitamin B6, folate, and vitamin B12.

More coffee fruit extract does not mean twice the benefit. A larger dose can change how a product acts, and the added vitamins make Plus a new mix.

No finished-product trial of Plus appears in the published evidence. There is no sound way to claim it will match, beat, or extend the 100 mg/100 mg trial result.

Labels can also change. If you plan to buy Neuriva Original, check the Supplement Facts panel on the bottle. The study result applies to the 100 mg coffee-cherry and 100 mg PS mix used in the trial.

What the current labels say

Both labels name amounts for their primary active ingredients instead of hiding them in a proprietary blend. That makes them easier to compare.

A clear label does not show that a product can support brain health or support cognitive function. It also cannot prove that a product will enhance memory. Dose clarity is not clinical support.

The Plus label also carries pregnancy, medication, health-condition, and soy warnings.

Prevagen's current product page does not show a full warning and allergy panel in plain text. A current CVS list includes casein peptones, lactose, and soy peptones. An older NIH label said the capsules contained milk and soy. Because that NIH label is old, read the bottle you may buy.

How these brain supplements claim to support brain health

Brain function claims versus clinical evidence

Neuriva and Prevagen take different paths. The Neuriva trial formula pairs a plant extract with PS, a phospholipid in brain cell membranes. Prevagen relies on apoaequorin, a calcium-binding protein first identified in jellyfish.

Both brands offer a biological story about brain cells and brain cell health. A plausible mechanism is only a starting point.

A proposed effect in the human brain still needs human evidence. A mechanism alone does not show that an ingredient crosses the blood brain barrier or improves cognitive performance.

For a memory claim to hold up, the full oral product should be tested at the sold dose against placebo. The main goals should be set before testing, the result should matter in daily life, and another group should repeat the work.

Like most brain supplements, neither brand clears that full bar. Neuriva has one short trial with mixed results and no independent repeat. Prevagen has one main trial, a dispute over how its findings were used, and a later court loss over ad support.

OTC brain supplements may promise mental clarity, sharper focus, and cognitive support, but those claims do not establish better cognitive performance or brain health.

Phrases such as brain performance and cognitive enhancement are still marketing. A claim to enhance cognitive function remains marketing unless a matching product trial shows better cognitive performance or brain health.

Clinical trials: Prevagen vs Neuriva finished-formula evidence

Both trials used random assignment, placebo, and blinding. A placebo controlled clinical trial can reduce bias, but its design is not the whole story.

The outcomes, label match, length, funding, and later checks all matter. Turning those differences into a simple star score would be false precision.

What the Neuriva trial found

The full Neuriva trial report was published in 2023. It enrolled 138 healthy adults ages 40 to 65 with self reported memory problems. These were self perceived memory problems, not diagnosed dementia or marked impairment. The trial lasted six weeks.

The test product supplied 100 mg of whole coffee cherry extract and 100 mg of PS each day.

Cognitive performance and everyday memory

The positive results were narrow. The Neuriva group improved more than placebo on selected measures within cognitive domains, including accuracy and reaction time outcomes in a numeric working-memory task.

The group also improved more on overall picture-recognition accuracy. A statistically significant improvement on a selected task is not proof of broad daily benefit.

Most measured scores did not differ between groups. There was no group difference in plasma BDNF.

There was also no group difference on the Everyday Memory Questionnaire, which asked about memory slips in normal life.

The Go/No-Go tests of attention and control were null too.

A faster answer on a computer task may not feel like better memory at home or work. The trial gives a signal worth more study.

It does not show that Neuriva can reverse cognitive decline, prevent age related cognitive decline, stop lost keys, or make names easier to recall.

Reckitt paid for the research and the paper's rapid service fee. Four authors worked for Reckitt.

A company-funded study can still be sound, but one short trial needs an independent repeat. The authors called for larger and longer studies.

The safety data were short term. The number of people reporting an event was close in the two groups. One dry-mouth event was seen as possibly tied to Neuriva, and all events resolved by the end.

That supports “generally well tolerated for 42 days in this group.” It does not establish safety for everyone or for long-term use.

What the Prevagen trial—and the court—say

The published Madison Memory Study tested apoaequorin against placebo for 90 days. It included 218 adults ages 40 to 91 who reported memory concerns.

The abstract reports gains in verbal learning and delayed recall and says apoaequorin was well tolerated.

Read alone, that sounds like a clean win. The full legal history makes it far less clear.

Claims, subgroups, and clinical support

The FTC's 2017 complaint said the full group showed no statistically significant improvement on any of nine computer tasks. It said the positive ad story came from more than 30 later subgroup checks.

A subgroup can reveal a true pattern, but repeated checks raise the chance of a result by luck. The complaint was an allegation at that stage, not the final ruling.

The case later went to trial. A November 2024 federal judgment says the jury found no competent and reliable scientific evidence supporting any of eight challenged statements.

They included claims that Prevagen improves memory, is clinically shown to do so, works within 90 days, reduces age-linked memory problems, or provides other cognitive benefits. The court ordered the defendants to stop those and similar claims. That record does not make Prevagen clinically proven.

The ruling should not be stretched past its words. The court did not ban Prevagen or make a blanket finding that every consumer experience amounted to false and unsubstantiated claims.

The judgment says there was no evidence of actual harm or economic injury and no claim for or evidence of damages. That does not establish safety or efficacy; the ruling addressed support for the challenged ads.

Still, that support question is central to a buying choice. Prevagen's main reason for sale is a memory claim. When a jury finds that none of the challenged claims was supported by competent and reliable scientific evidence, the label dose and brand fame do not fill the gap. The trial may hold ideas for future work, but it does not give a strong base for a broad promise to buyers.

What the ingredient research adds

Coffee fruit extract and BDNF

Neuriva ads often focus on BDNF, short for brain-derived neurotrophic factor. BDNF helps nerve cells grow, adapt, and form links. That makes it a useful research marker. It does not make a rise in blood BDNF the same thing as better memory.

In a small single-dose study, a pooled group of 10 people took 100 mg of whole coffee fruit extract. Plasma BDNF rose 143% from the starting level. The size of that number is eye-catching. The study was tiny, the dose was taken once, and the outcome was a blood marker. No gain in daily memory was shown. The authors said larger trials were needed.

The finished Neuriva trial is even more useful here. It tested the product for 42 days and found no BDNF difference from placebo. So “raises BDNF” should not be turned into “improves memory.” It should not be treated as a proven effect of long-term Neuriva use.

Phosphatidylserine

Phosphatidylserine (PS) is a phospholipid found in cell membranes, including nerve-cell membranes. The 100 mg/100 mg Neuriva trial formula and current Plus each use 100 mg of PS. Human research on PS is mixed.

One 12-week trial gave 120 older adults either placebo, 300 mg of soy PS, or 600 mg. It found no group difference on memory or other thinking tests. A six-month trial in 78 adults tested 100 mg and 300 mg. Scores rose in all groups, including placebo. People with lower scores at the start showed a benefit signal in the PS groups.

Those studies do not cancel each other out. They used different groups, doses, lengths, and tests, and neither tested Neuriva's phosphatidylserine formulation. The fair summary is “mixed,” not “proven” or “useless.”

Apoaequorin and vitamin D

Apoaequorin can bind calcium. Calling it a “jellyfish derived protein” describes its discovery story, not proof that a swallowed protein reaches the brain in a useful form. It also does not show better memory. The human product trial and court record carry more weight than the mechanism.

Prevagen Regular Strength also gives 50 mcg, or 2,000 IU, of vitamin D. Vitamin D matters for bone, muscle, nerve, and immune health. It should not be read as proof of a memory effect. The adult upper limit is 100 mcg, or 4,000 IU, per day from all sources. That means one Prevagen capsule uses half of that limit before food or any other supplement is counted.

Safety, side effects, and interactions

Short product trials can identify common issues during the test. They cannot rule out rare events or harm that may take months or years to show.

Neuriva's trial lasted 42 days. Prevagen's lasted 90 days. Prevagen also points to rat and lab safety work, but animal studies do not prove long-term safety in people.

Neuriva Plus has the clearer public warning. It says adults age 18 and older should take one capsule daily. It also says not to take it while pregnant or breastfeeding, while on medicine, or with a known health condition unless a doctor has been asked. It contains soy.

Prevagen's 50 mcg of vitamin D adds to every other source in your day. Vitamin D can interact with some drugs, including thiazide water pills, steroids, orlistat, and some statins. A pharmacist can help add up your total and check your drug list.

Food allergy details deserve care too. Current retailer data for Prevagen Regular Strength list casein peptones, lactose, and soy peptones. An old NIH label used a direct milk-and-soy warning, but labels can change. Do not rely on an old web page if milk or soy could cause a serious reaction. Read the label and warning panel on the bottle or call the maker before use.

Brain fog, cognitive health, and when to seek care

Experiencing brain fog does not identify a cause. Depression, medication reactions, and thyroid, liver, or kidney problems can impair memory. Because some causes are treatable, new or worsening symptoms deserve evaluation instead of another supplement.

Cost and value

Price does not track proof. On August 24, 2026, Neuriva Plus cost $39.99 for 30 capsules at Target. Prevagen Regular Strength cost $39.95 for 30 capsules on its brand site. Both were about $1.33 a day. Different sellers and promotions can change the cost.

This compares two common shelf choices, not the Neuriva trial mix with Prevagen. A lower price does not improve the evidence. For value, ask what outcome is supported at this dose.

The 100 mg/100 mg Neuriva formula produced selected computer-task gains over 42 days but no clear change in reported daily memory. Prevagen's abstract is positive, but broad claims tied to its study failed the 2024 court test. Neither looks like a sure monthly buy.

Which one makes more sense for you?

Neuriva Original has the better research fit only if its label matches the 100 mg coffee-cherry and 100 mg PS trial mix. Neuriva users should verify both amounts instead of relying on the brand name. Even so, the study was short, mixed, and paid for by the maker's parent company.

Current Neuriva Plus is not a stand-in. It has 200 mg of coffee fruit extract and added B vitamins, but no finished-product Plus trial shows that those changes improve the result. Buying Plus because of the 100 mg/100 mg trial is a poor match.

Prevagen Regular Strength has a simple one-capsule label, but its memory pitch is the weak spot. The published study cannot be separated from the later court finding. Brand age and jellyfish language do not fix that issue.

You may be better off skipping both if you want a clear, repeated effect on everyday memory. If your aim is calm focus rather than memory care, the guide to the best L-theanine supplements covers a different product group and its research doses. You can also browse the Best Brain Doping guide index.

Common questions

Is Neuriva better than Prevagen?

The 100 mg/100 mg Neuriva formula has a slight evidence edge because it was tested in a randomized trial and showed gains on selected computer tasks. An Original bottle must match that formula for the study to fit. The study also had null results, lasted only 42 days, and was company-funded. That is not strong proof of a daily-memory benefit.

Did a court say Prevagen does not work?

Not in those words. The 2024 judgment says the jury found that none of eight challenged memory and thinking claims was supported by competent and reliable scientific evidence. The court ordered those or similar claims stopped. It did not ban the product, and the judgment says there was no evidence of actual harm or economic injury.

Can Neuriva Plus use the Neuriva Original study?

Only as limited background, not direct proof. The trial used 100 mg of whole coffee cherry extract and 100 mg of phosphatidylserine. Current Plus uses 200 mg of coffee fruit extract, 100 mg of phosphatidylserine, and added B vitamins. The finished formulas are not the same.

Do either of these supplements prevent dementia?

No good evidence shows that they prevent or treat dementia. Neither product is an FDA-approved dementia drug. Memory changes that are new, worse, or hard to manage should be checked by a health professional.

How long would it take to notice a change?

The Neuriva trial lasted 42 days, while the Prevagen study lasted 90 days. Those study lengths do not promise that a buyer will feel a change by a set date. The Prevagen claim about improvement within 90 days was one of the statements covered by the 2024 judgment.

The bottom line

Neither product has strong evidence for a meaningful everyday-memory benefit. The matching 100 mg/100 mg Neuriva formula has a narrow trial edge; current Plus differs, and Prevagen's challenged claims lacked adequate support.

If you still want to try one, Neuriva Original is the closer match only when its current label matches the 100 mg/100 mg trial mix. You also need to accept how limited the study is. For real memory concerns, the best next step is not a stronger bottle. It is a careful medical check.